Research programme: fatty acid synthase inhibitors - FASgen

Drug Profile

Research programme: fatty acid synthase inhibitors - FASgen

Alternative Names: C-75; FAS 093; FAS 115; FAS 20013; FAS 267; FAS 31; FAS 89B; FAS-031; FAS-247; FAS183; FAS57

Latest Information Update: 17 Dec 2013

Price : $50

At a glance

  • Originator Johns Hopkins University
  • Developer FASgen Inc
  • Class
  • Mechanism of Action Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Diabetes mellitus; Obesity; Tuberculosis
  • Discontinued Stroke

Most Recent Events

  • 17 Dec 2013 No development reported - Preclinical for Tuberculosis in USA (PO)
  • 17 Dec 2013 No development reported - Preclinical for Obesity in USA (PO)
  • 17 Dec 2013 No development reported - Preclinical for Diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top